MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

Risovalisib

產(chǎn)品活性：Risovalisib (CYH33) 是一種具有口服活性的，高選擇性 PI3Kα 抑制劑，對 α/β/δ/γ 亞型的 IC₅₀ 分別為 5.9 nM/598 nM/78.7 nM/225 nM。Risovalisib 抑制 Akt 和 ERK 的磷酸化，并顯著誘導(dǎo)乳腺癌和非小細(xì)胞肺癌 (NSCLC) 細(xì)胞 G1 期阻滯。Risovalisib 具有有效的抗實體瘤的活性。

研究領(lǐng)域：PI3K/Akt/mTOR

作用靶點：PI3K

In Vitro: Risovalisib (CYH33) inhibits cell proliferation with IC₅₀s below 1?μM in 56% (18/32) of the breast cancer cell lines.
CYH33 (0.012-1 μM; for 24 hours) significantly arrests T47D and MCF7 cells in G1 phase in a concentration-dependent manner.
CYH33 (4-1000 nM; 1 hour) concurrently inhibits phosphorylation of ERK and Akt in both T47D and MCF7 cells.
CYH33 (0.11-1 μM; 24 hours) fails to induce apoptosis in MCF7 and MDA-MB-231?cells.

In Vivo: Risovalisib (CYH33) (2-20 mg/kg; oral; once a day for 21 days) potently restrains tumor growth in mice bearing human breast cancer cell xenografts.
Single administration of CYH33 (20?mg/kg; oral) significantly down-regulates the level of phosphorylated Akt in tumor tissues, demonstrating the suppression of PI3K signaling in nude mice.
CYH33 (10?mg/kg; oral; once a day for 18-d or 20-d respectively) delays the restoration of blood glucose and area under the curve (AUC) of blood glucose increased upon CYH33 treatment in T47D xenografts and R26-Pik3ca^H1047R;MMTV-Cre mice.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Umbralisib hydrochloride  |  PI3K-IN-22  |  Rigosertib sodium  |  PI3Kδ/γ-IN-2  |  PI3kδ inhibitor 1  |  GSK2292767  |  PI3K-IN-28  |  PI3K/mTOR Inhibitor-13  |  Disitertide diammonium  |  1,3-Dicaffeoylquinic acid  |  Quercetin dihydrate  |  PI3Kγ inhibitor 4  |  PI-103 Hydrochloride  |  Hirsutenone  |  Sophocarpine monohydrate  |  Heterophyllin B  |  IC-87114  |  Phosphatidylinositol 4,5-bisphosphate  |  Chaetominine  |  SF2523  |  Flupentixol  |  GNE-490  |  AZD-7648  |  Serabelisib  |  PI3K-IN-38  |  PI3Kα-IN-5  |  Boc-L-cyclobutylglycine  |  NIBR-17  |  PI3K/HDAC-IN-1

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實驗中心和嚴(yán)格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團(tuán)隊跟蹤新的制藥及生命科學(xué)研究進(jìn)展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機(jī)構(gòu)建立了長期的合作。